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Measure of benefits used in the economic analysis
The outcome measure used was quality-adjusted life-years (QALYs) gained. A decision-analytic model was used to assess the cost-effectiveness of captopril therapy. A Markov model was used to model the effectiveness of therapy on long-term prognosis by following a hypothetical cohort of patients (from the SAVE trial) through states of health and illness. The time trade-off valuation tool was used. During the course of the SAVE trial a sample of 82 study patients from one study site (Brigham and Women's Hospital in Boston) was used to assess time trade-off utilities.
Direct costs
Main quantities of resource use were analysed separately from the costs. Costs rather than charges were used in the analysis. All costs were converted to 1991 US dollars using the medical care component of the consumer price index (CPI). All costs were discounted. Costs estimates for the model were based on actual resource utilisation of trial patients after adjusting for protocol-driven costs associated with outpatient visits. Professional and hospital costs were calculated on the basis of average length of stay using the median reimbursement rates. The cost of captopril therapy was based on the average daily dose in mg of all SAVE patients assigned to captopril therapy and consisted of an acquisition cost for a full dose of 50mg three times daily, plus a dispensing cost per month supply. Costs of outpatients tests were assumed to be equal under both strategies and were thus not modelled explicitly.
Statistical analysis of costs
Costs were treated in a stochastic way. Standard deviations, mean values and a 95% confidence interval (CI) were reported.
Currency

US dollars ($).
Sensitivity analysis
One-way sensitivity analyses were carried out on all survival benefit, utility and cost estimates over wide ranges. Included in the analyses were the scenario of no survival benefit with costs being incurred beyond 4 years ('limitedbenefit' scenario), additional benefits beside costs ('persistent-benefit' scenario) and a 'worst-case' scenario. 
Estimated benefits used in the economic analysis
Under the 'limited-benefit' scenario, the average (discounted) QALYs ranged from 3.96 to 8.13 for the captopril strategy and from 3.44 to 8.10 for the no captopril strategy. The 'limited-benefit' scenario yielded corresponding ranges of 4.33 -8.34 (captopril) and 3.44 -8.10 (no captopril). These estimated average benefits reflect discounting of benefits beyond 1 year at a 5% annual rate, and the lower bounds refer to 80 year old patients, with the upper range limits referring to 50 year olds.
Cost results
Under the 'limited-benefit' scenario, the total average costs for captopril ranged from $16,699, for 80 year old patients, to $32,098, for 50 year old patients; the no-captopril strategy had associated costs ranging from $14,844, for 80 year olds, to $30,369, for patients aged 50. The 'persistent-benefit' scenario yielded total average costs ranging from $14,844 to $30,369; the no captopril option had the same costs (and, therefore, cost range) as those reported for this strategy under the 'limited-benefit' scenario. All the cost figures are expressed in 1991 prices and reflect annual cost discounting at a 5% rate.
Synthesis of costs and benefits
In the 'limited-benefit' analyses, the incremental (discounted) cost per additional (discounted) quality-adjusted life-year (QALY) gained (ICER) of captopril therapy (relative to no captopril) ranged from $3,600/QALY for 80 year old patients to $60,800/QALY for 50 year old patients. In the 'persistent-benefit' analyses, the ICER ranged from $3,700 to $10,400/QALY, depending on age. In the 'worst-case' analysis, the ICER for captopril therapy remained favourable ($8,700 to $29,200/QALY) for 60 to 80 year old patients but was higher ($217,600/QALY) for 50 year old patients. In the limited-benefit analyses, patients aged 60 to 80 were not sensitive to changes in parameter values. If captopril cost $1,000/year, the ICER increased to $180,800/QALY. In the persistent-benefit analyses, increasing the cost of captopril therapy for the 50 year old patients to $1,000/year yields an ICER of $24,900/QALY. In the 'worst-case' scenario, with a 1% lower quality adjustment (utility), the cost-effectiveness of captopril therapy remained favourable in patients aged over 60. The ICER for 50 year old patients was $217,600/QALY. For 60 year old patients it was $29,200/QALY, and for the 70 and 80 year old patients it was $13,700/QALY and $8,700/QALY, respectively. These represent 1991 prices. A 5% discount rate was applied to both costs and benefits.
